A first-of-its-kind clinical trial published in Cell suggests that CAR-T-cell therapy enriched with stem-cell memory T cells may be more potent and less toxic than standard treatments for blood cancers. In the small study, 5 of 11 patients with difficult-to-treat blood cancers achieved full remission, compared to just 1 of 10 given conventional CAR-T-cell therapy at similar doses. Crucially, participants also avoided the harsh pre-treatment drugs typically required and experienced milder side effects, including reduced cytokine release syndrome.

Researchers increased the proportion of stem-cell memory T cells nearly tenfold, producing what immunologist Susan Kaech called "a more powerful product, pound for pound." Lead researcher Luca Gattinoni is now planning follow-up trials across other cancer types, including solid tumours, historically harder to treat with CAR-T-cell therapy, where the enriched approach faces its next major test.

"Achieving five full remissions from eleven patients, at lower doses and without standard pretreatment, is a good early signal that stem-cell memory T cell enrichment could meaningfully redefine the CAR-T-cell therapeutic benchmark. If this approach can replicate its potency against solid tumours, where conventional CAR-T-cell therapy has consistently fallen short, it would mark a true inflection point for cancer immunotherapy."

Nimit Mistry and others

AstraZeneca has committed £300m to its Cambridge and Macclesfield facilities after suspending major capital projects in 2025 over NHS pricing disputes. The resumption follows government negotiations, with Cambridge receiving the previously paused GBP £200M expansion and Macclesfield securing an additional GBP £100M.

Prime Minister Keir Starmer told Parliament the deal would "future proof thousands of jobs," crediting a pharmaceutical arrangement with the US for enabling the commitment. CEO Pascal Soriot announced plans for a "lab of the future" at Macclesfield, using digital and data tools to accelerate drug development, while Cambridge will gain data analysis and molecular science staff.

Susannah Streeter of Wealth Club called the Cambridge restart "highly symbolic," suggesting the UK's pharma investment climate is shifting. The news coincides with AstraZeneca reporting strong Q1 2026 results, 8% revenue growth to USD $15.3B, as the company targets USD $80B in total sales by 2030.

Incyte has secured FDA approval for Jakafi XR, an extended-release version of its blockbuster JAK inhibitor ruxolitinib. Approved across the same indications as the original, myelofibrosis, polycythemia vera, and graft-versus-host disease, the once-daily 55mg tablet matches the exposure profile of a twice-daily immediate-release dose. Commercially available from 8 May, Jakafi XR is strategically significant for Incyte as its original formulation approaches a 2028 patent cliff.

Meanwhile, Lannett and Sunshine Lake Pharma have won FDA approval for Langlara, a biosimilar of Sanofi's long-acting insulin Lantus, and the first insulin from a Chinese manufacturer to receive FDA clearance. Approved for type 1 and type 2 diabetes across adult and paediatric patients, Langlara also carries an interchangeable designation, allowing pharmacists to substitute it for Lantus without a physician's authorisation, broadening access to more affordable insulin options.

AI is swiftly moving from a hypothetical adjunct in drug discovery to an integrated technology across the development process. AstraZeneca has reported that its generative AI framework has halved the time needed to identify molecular structures that could become potential new medicines. Bristol Myers Squibb expects to deliver a 30% reduction in clinical development cycle times with AI by streamlining clinical operations, shortening development timelines, and improving quality oversight.

The most interesting trend is that AI can act as a collaborator, not an authority. Research from the Swiss Federal Technology Institute of Lausanne, published in Matter, points in that direction. Chemists at the institute developed a new LLM tool, called Synthegy, that allows chemists to describe synthesis goals in plain language, while the system ranks between human strategy and chemical possibility. While molecules must still survive biology, manufacturing, and trials, the direction is clear: leaders in the field are embedding AI as a key partner into scientific workflows, and the impact is tangible.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Eli Lilly has signed a deal worth up to USD $2.25B with California AI start-up Profluent, targeting a next-generation approach to gene editing that goes beyond the limitations of CRISPR and base editing.

Founded in 2022, Profluent uses AI models and large language models to design recombinase editors capable of inserting kilobase-scale stretches of DNA at precise genomic locations, a capability current tools cannot reliably achieve. The approach could address diseases driven by hundreds of different mutations using a single therapeutic, rather than requiring a separate editor for each variant.

Lilly gains an exclusive licence to advance selected recombinases through preclinical and clinical development into commercialisation. Financial and programme details remain limited. The deal deepens Lilly's expanding gene-editing portfolio, which already includes a USD $1.2B recombinase partnership with Germany's Seamless Therapeutics and its USD $700M Boston-based Lilly Institute for Genetic Medicine, opened in 2024.

JPMorgan has initiated coverage of Arrowhead Pharmaceuticals with an Overweight rating and an $88 price target, implying around 20% upside. Analyst Brian Cheng cited the company's diversified RNAi pipeline, spanning cardiovascular disease, obesity, neurodegeneration, and rare diseases, as the core investment case.

The near-term anchor is REDEMPLO, Arrowhead's first commercial product, FDA-approved in November 2025 for Familial Chylomicronemia Syndrome. Over 100 prescriptions were written through February 2026, with most patients new to the drug class. Bigger still, Phase III results for plozasiran in severe hypertriglyceridemia, a market management values at USD $3–4B, are expected in Q3 2026.

Longer-term catalysts are building too. Obesity candidate ARO-INHBE roughly doubled weight loss versus tirzepatide alone in early data, while Alzheimer's programme ARO-MAPT recently dosed its first patients, with initial readouts anticipated later this year.